Periorbital edema associated with alpelisib

Elizabeth A. Dao; Saira J. George; Meghan M. Heberton; Omar Pacha; Craig A. Kovitz; Anisha B. Patel; Rhea M. Phillips

doi:10.1016/j.ctarc.2022.100596

Periorbital edema associated with alpelisib

Elizabeth A. Dao, Saira J. George, Meghan M. Heberton, Omar Pacha, Craig A. Kovitz, Anisha B. Patel, Rhea M. Phillips

Research output: Contribution to journal › Article › peer-review

Abstract

Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.

Original language	English (US)
Article number	100596
Journal	Cancer Treatment and Research Communications
Volume	32
DOIs	https://doi.org/10.1016/j.ctarc.2022.100596
State	Published - Jan 2022
Externally published	Yes

Keywords

Alpelisib
Breast cancer
Cutaneous adverse events
Dermatology
Phosphatidylinositol 3-kinase inhibitors

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ctarc.2022.100596

Cite this

@article{650fade4a58e47c2bbf684e3f225b6d7,

title = "Periorbital edema associated with alpelisib",

abstract = "Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.",

keywords = "Alpelisib, Breast cancer, Cutaneous adverse events, Dermatology, Phosphatidylinositol 3-kinase inhibitors",

author = "Dao, {Elizabeth A.} and George, {Saira J.} and Heberton, {Meghan M.} and Omar Pacha and Kovitz, {Craig A.} and Patel, {Anisha B.} and Phillips, {Rhea M.}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jan,

doi = "10.1016/j.ctarc.2022.100596",

language = "English (US)",

volume = "32",

journal = "Cancer Treatment and Research Communications",

issn = "2213-0896",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Periorbital edema associated with alpelisib

AU - Dao, Elizabeth A.

AU - George, Saira J.

AU - Heberton, Meghan M.

AU - Pacha, Omar

AU - Kovitz, Craig A.

AU - Patel, Anisha B.

AU - Phillips, Rhea M.

PY - 2022/1

Y1 - 2022/1

N2 - Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.

AB - Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.

KW - Alpelisib

KW - Breast cancer

KW - Cutaneous adverse events

KW - Dermatology

KW - Phosphatidylinositol 3-kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85133796113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133796113&partnerID=8YFLogxK

U2 - 10.1016/j.ctarc.2022.100596

DO - 10.1016/j.ctarc.2022.100596

M3 - Article

C2 - 35834907

AN - SCOPUS:85133796113

SN - 2213-0896

VL - 32

JO - Cancer Treatment and Research Communications

JF - Cancer Treatment and Research Communications

M1 - 100596

ER -

Periorbital edema associated with alpelisib

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this